InvestorsHub Logo

pepeoil

08/05/21 9:15 AM

#156334 RE: captbob2112 #156333

Gotta be pumpin sumpin. Lol. Bubbie got get more consulting fees and shares. Lol.

toncatmad

08/05/21 9:44 AM

#156338 RE: captbob2112 #156333

Wow so we are back to the same old GAG of an RXAIR spinoff lol. Didn’t they try that lie once before?
Man these guys are too much. First they say about spending loads of money in R&D but those numbers never seem to show up in the financials. The last money spent on R&D was long before the Rottens ever came into the picture. Then they are going to spin-off a company that has barely made any money at all.
I can’t wait for the new financials to see if there is any money coming in other than Rotmans sales and to see this new claim of R&D money being spent lol

King Zurich

08/05/21 9:52 AM

#156340 RE: captbob2112 #156333

I am having a hard time understanding why this is not great news for current and future Vystar shareholders. If you are a current Vystar shareholder and have 1M shares you can sell today at $20,000. If you hold until January 5, you get and additional $60,000 of Rx Air stock making the effective price of Vystar today at 8 cents. Think selling will dry up. On the other hand the only way to acquire RxAir shares is to buy Vystar shares over the next few months. Buying will go up and a supply demand imbalance will occur.
Vystar is also giving 80% of the RxAir shares to Vystar shareholders while retaining 20%. This allows for the dividend to be tax free and any taxes on subsequent sales are pushed to 2023 which is neat.
The $2.00 per share opening price is a given as that is the price of the last Private tranche according to the press release and the share base is only 35-36M and not 1.2B
Should be an interesting few months to see if the supply demand imbalance develops.